FDA approves LO LOESTRIN FE tablets for oral contraception

Oct 25 2010NewsGuard 100/100 Score

Warner Chilcott plc (Nasdaq: WCRX) today announced that the United States Food and Drug Administration (FDA) has approved LO LOESTRIN™ FE (norethindrone acetate and ethinyl estradiol tablets, ethinyl estradiol tablets and ferrous fumarate tablets) for the prevention of pregnancy.  LO LOESTRIN FE is a novel oral contraceptive that offers women the lowest dosage of estrogen (10 mcg) of any oral contraceptive currently available in the U.S. market.  

"We are excited about the approval of LO LOESTRIN FE, which complements our women's healthcare franchise and expands the product offerings in our branded oral contraceptive portfolio," said Roger Boissonneault, President and CEO of Warner Chilcott.

The Company anticipates the commercial launch of LO LOESTRIN FE in early 2011.

SOURCE Warner Chilcott plc

Posted in: Women's Health News | Pharmaceutical News

Tags: , , , , , , , , , ,

Comments (0)

Suggested Reading

Tibetan women’s high-altitude adaptations drive greater reproductive success
Ketamine clinics show inconsistent practices on pregnancy and contraception
Marylanders to vote on expansive ‘right to reproductive freedom’
If lawsuit ends federal mandates on birth control coverage, states will have the say
Inside project 2025: Former Trump official outlines hard right turn against abortion
Study reveals gaps in contraception access despite 12-month supply policies
Hydrogel implant technology offers new hope for women seeking reversible sterilization and endometriosis treatment
Nepalese women in Japan face challenges in accessing sexual and reproductive health services

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Study reveals high failure rate for tubal sterilization as birth control